A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).

Authors: Jason J. Luke, Ardy Davarifar, Yana G. Najjar, Omid Hamid, Dirk Schadendorf, Michael K.K. Wong, Nikhil I. Khushalani, Paolo Antonio Ascierto, Tawnya Lynn Bowles, Mark Navarro, Giuseppe Gullo, Caroline Robert

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9599

Source: Full article

---

Abstract

TPS9599